Irish pharmaceutical cannabis manufacturer Dunbar Pharmaceuticals has today launched the first plant-derived dronabinol active ingredient into the UK market.
Curaleaf Laboratories, one of the UK’s leading providers of medicinal cannabis products, is pleased to announce a landmark partnership with Australian Natural Therapeutics Group (ANTG), one of Australia’s most respected producers of pharmaceutical-grade medicinal cannabis.
Cookies, the most globally recognised cannabis brand, is entering global medical markets with a full extract portfolio through a strategic partnership with SOMAÍ, a leading EU-GMP-certified vertically integrated Multi-Country Operator (MCO).
Germany’s telemedicine-fuelled expansion has driven the value of its medical cannabis market up by hundreds of millions of euros in just less than two years.
Airo Brands, a US multi-state CPG company focused on proprietary cannabis products, in partnership with Jupiter Research LLC, has received regulatory approval for its CE-marked Class IIa medical handheld liquid inhalation device, the Airo Medical Inhalation System, across Europe and Australia.
As Europe’s medical cannabis market shifts from a focus on growth to pharmaceutical discipline, PHCANN International has emerged as a leading voice in this new phase.
Despite being one of the earliest countries in Europe to legalise cannabis for medical use, not to mention having an ideal climate for cultivation, Greece’s market only came online in practice last year.
In the first of a series of interviews focused on the expert contributors to Prohibition Partners’ newly launched Insights Hub, we sat down with Linnea to discuss the increasing importance of GMP certification and pharmaceutical discipline in a rapidly growing cannabis market.
Grow Group, one of the UK’s leading medical cannabis distributors now supplying over 10,000 patients internationally, announced a major strategic shift to bring control of its operations entirely in house.
